Vantia Therapeutics’ lead candidate VA106483 demonstrates positive anti-diuretic effect in Phase IIa trial in nocturia

30-Jun-2009 - United Kingdom

Vantia Therapeutics announced positive results from a Phase IIa clinical trial of its lead development compound VA106483 for nocturia. The trial showed that oral VA106483 was successful in producing a predictable and sustained anti-diuretic effect in patients, as determined by increased osmolality and decreased urine output. The study also found that VA106483 was generally well tolerated among the patient population.

VA106483 is a novel small molecule drug candidate that exerts its effect directly in the kidney by binding to vasopressin (V2) receptors, which regulate water balance. It was discovered by Vantia from its drug candidate library.

The double-blind, placebo-controlled, dose-response study was designed to investigate the pharmacodynamics and pharmacokinetics of single and repeated oral doses of VA106483. The trial involved 27 elderly men aged 65 years or more with a history of nocturia.

Based on these results, Vantia now plans to advance VA106483 into a larger Phase IIb clinical efficacy study in the second half of 2009.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances